植入式心律转复除颤器在连续流左心室辅助装置桥接移植患者中的作用:倾向评分匹配分析
该研究基于UNOS注册数据,纳入2004年5月至2014年4月期间接受连续流左心室辅助装置(CF-LVAD)作为桥接移植的患者,经倾向评分匹配后比较有无植入式心律转复除颤器(ICD)患者的结局。结果显示,ICD的存在并未降低CF-LVAD支持期间的死亡率,且因病情过重而除名或移植概率均无差异。
要点
- 在CF-LVAD桥接移植患者中,ICD未显示生存获益。
- 调整因设备并发症需升级UNOS列表状态后,结果仍无显著差异。
- ICD与因病情过重除名风险及移植概率均无显著关联。
核心结论
- 在连续流左心室辅助装置桥接移植的患者中,植入式心律转复除颤器的存在并未降低死亡率。
研究设计与样本
- 回顾性队列研究,使用UNOS注册数据,纳入2004年5月至2014年4月期间接受LVAD作为桥接移植的患者,随访至2014年6月。
- 研究队列共2990例患者,经倾向评分匹配后识别出1012例具有相似倾向评分的患者。
主要发现
- 有无ICD患者在接受设备支持期间的生存率无差异(HR=1.20;95%CI 0.66-2.17;p=0.55)。
- 调整因设备并发症需升级UNOS列表状态后影响极小(HR=1.11;95%CI 0.60-2.05;p=0.74)。
- ICD患者因病情过重而除名的风险未增加(HR=1.08;95%CI 0.63-1.86;p=0.78)。
- 移植概率相似(HR=1.05;95%CI 0.87-1.27;p=0.62)。
临床怎么用
- 对于连续流左心室辅助装置桥接移植的患者,ICD的存在不应被视为改善生存的必要措施,临床决策需个体化评估。
局限性
- 研究为回顾性注册数据分析,可能存在未测量的混杂因素;倾向评分匹配仅能控制已测量变量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Implantable cardioverter defibrillators (ICDs) provide a significant mortality benefit for appropriately selected patients with advanced heart failure. ICDs are associated with a mortality benefit when used in patients with a pulsatile left ventricular assist device (LVAD). It is unclear whether patients with a continuous-flow LVAD (CF-LVAD) derive the same benefit. We sought to determine if the presence of an ICD provided a mortality benefit during CF-LVAD support as a bridge to transplantation. METHODS: Patients were identified in the United Network for Organ Sharing (UNOS) registry who underwent LVAD implantation as bridge to transplantation between May 2004 and April 2014, with follow-up through June 2014. Primary outcome was freedom from death while on CF-LVAD support with adjustment for complications requiring UNOS listing status upgrade. Secondary end-points included freedom from delisting while on CF-LVAD support and incidence of transplantation. RESULTS: The study cohort comprised 2,990 patients, and propensity score matching identified 1,012 patients with similar propensity scores. There was no difference in survival during device support between patients with and without an ICD (hazard ratio [HR] = 1.20; 95% confidence interval [CI], 0.66-2.17; p = 0.55). Adjusting for device complications requiring a UNOS listing status upgrade had minimal influence (HR = 1.11; 95% CI, 0.60-2.05; p = 0.74). There was no increased risk of delisting owing to being too sick for patients with an ICD (HR = 1.08; 95% CI, 0.63-1.86; p = 0.78). Likewise, the probability of transplantation was similar (HR = 1.05; 95% CI, 0.87-1.27; p = 0.62). CONCLUSIONS: Among patients bridged to transplantation with a CF-LVAD, the presence of an ICD did not reduce mortality.
引用
- Clerkin KJ, Topkara VK, Mancini DM, et al. The role of implantable cardioverter defibrillators in patients bridged to transplantation with a continuous-flow left ventricular assist device: A propensity score matched analysis. J Heart Lung Transplant. 2016. PMID: 28089072. doi:10.1016/j.healun.2016.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。